New Zealand's CoDa Therapeutics has raised $10 million in venture capital, raising its total first round financing to $20 million. Domain Associates and GBS Ventures led the round and much of the money has been earmarked for clinical trials of its tissue repair program.
- read the report on the round from the New Zealand Herald
ALSO: REGiMMUNE has raised $4.2 million in its second round of venture capital financing. The original lead investor NIF SMBC Ventures led the round. Release
PLUS: SV Life Sciences, formerly Schroder Ventures Life Sciences, today announced the final closing of SV Life Sciences Fund IV with total commitments of $572 million. Release